PRRT2 variants and effectiveness of various antiepileptic drugs in self-limited familial infantile epilepsy

Self-limited familial infantile epilepsy (SFIE), formerly referred to as benign familial infantile seizures or benign familial infantile epilepsy [1, 2], is an epilepsy syndrome characterized by the onset of seizures in the infantile period at 3–12 months of age. The outcome of these seizures is usually benign, without affecting normal development and with no consequent cognitive impairment. The self-limited familial and non-familial forms of infantile epilepsy are identical except for the presence of a family history [3].The other main clinical features of SFIE include non-febrile seizures and clusters of brief focal seizures, which can progress to secondarily generalized seizures [4–6].

0